Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
The WBAA Classical 101.3 and WBAA News 105.9 tower will be undergoing major work starting on March 7th to enhance and strengthen the tower. The work is expected to continue until approximately March 30th. Most of the work will be done while the stations are at full power, but there will be times where we will need to reduce power or be off the air so that crews can work safely. We thank you for your patience while this work is completed. You can still listen to WBAA Classical and WBAA News online or via the WBAA mobile app.

U.K. clears 6th COVID shot despite canceling deal for doses

Laboratory technicians work at the Valneva headquarters in Saint-Herblain, western France, Wednesday, Feb.3, 2021.
David Vincent
/
AP
Laboratory technicians work at the Valneva headquarters in Saint-Herblain, western France, Wednesday, Feb.3, 2021.

LONDON — British authorities have authorized a coronavirus vaccine for adults made by French drugmaker Valneva, despite the government's decision last year to cancel an order for at least 100 million doses.

The U.K. is the first country to authorize Valneva's vaccine, which is also under review by the European Medicines Agency. Britain's medicines regulator said Thursday that the two-dose vaccine is intended for adults ages 18 to 50, with the second dose given about a month after the first.

The Valneva vaccine is made with the decades-old technology used to manufacture shots for flu and polio. It is the sixth COVID-19 vaccine the U.K. has cleared and the only one that utilizes a "killed" virus; scientists grow the coronavirus in a lab and then inactivate the virus so it cannot replicate or infect cells.

The U.K. government scrapped an agreement with Valneva in September to purchase at least 100 million doses, saying at the time that British regulators probably would not cleared the shot. Valneva said Britain canceled the deal because of supply concerns.

Health Secretary Sajid Javid said in September that he couldn't go into details because of commercial issues but that the deal was spiked because "it was also clear to us that the vaccine in question that the company was developing would not get approval."

Britain was an early backer of the Valneva vaccine, agreeing to invest millions of pounds in a production facility in Scotland. As part of the contract, the U.K. had agreed to buy 100 million doses with options for another 90 million.

Even without the Valneva vaccine, the government has acquired more than enough doses to fully vaccinate everyone in the country twice. To date, nearly 60% of the British population has received three doses.

Copyright 2022 NPR. To see more, visit https://www.npr.org.

Tags
The Associated Press
[Copyright 2024 NPR]